Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Values First Advisors Inc.

Values First Advisors Inc. lowered its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 24.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,249 shares of the biopharmaceutical company’s stock after selling 6,698 shares during the quarter. Values First Advisors Inc.’s holdings in Sage Therapeutics were worth $115,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp lifted its stake in shares of Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after purchasing an additional 451,377 shares during the period. RTW Investments LP lifted its position in Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after buying an additional 111,123 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Sage Therapeutics by 10.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock worth $3,265,000 after buying an additional 43,617 shares during the period. Geode Capital Management LLC boosted its stake in Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock worth $8,975,000 after buying an additional 3,757 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Sage Therapeutics in the 3rd quarter valued at about $473,000. 99.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on SAGE shares. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday. Canaccord Genuity Group lowered their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday. Oppenheimer dropped their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday, October 30th. Finally, Truist Financial reduced their target price on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Sage Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.65.

Sage Therapeutics Stock Down 0.4 %

Shares of NASDAQ:SAGE opened at $7.16 on Thursday. The company has a 50 day moving average of $6.34 and a two-hundred day moving average of $6.93. Sage Therapeutics, Inc. has a 52-week low of $4.62 and a 52-week high of $27.39.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. Research analysts anticipate that Sage Therapeutics, Inc. will post -6.46 EPS for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.